, Volume 216, Issue 2, pp 187–196 | Cite as

Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial

Original Investigation



Existing nicotine replacement therapies (NRT) improve the chances of smoking cessation but are limited by either relatively slow nicotine absorption rates or unpleasant side effects, leaving scope for the development of more effective and acceptable products.


This study aimed to test the acceptability and effectiveness for withdrawal symptom relief of a novel nicotine delivery device, the ‘Nicotine Cannon’ (NC), compared with three existing, equivalent products: the nicotine lozenge, mini-lozenge and nicotine inhalator.


A repeated-measures crossover trial where participants were randomised to one of two conditions (1- or 10-h abstinence) and in each condition to one of 24 possible sequence permutations to test each product for 10 min was carried out. Standard sociodemographic and smoking characteristics were assessed as well as withdrawal and NRT use symptoms before, during and after NRT use and product satisfaction after use.


The results were similar across both durations of abstinence. The NC was significantly more effective than the inhalator in reducing withdrawal symptoms (F(3, 196) = 3.5, p = 0.015) and together with the mini-lozenge performed better than other NRT in alleviating urges to smoke (F(3, 563) = 9.6, p < 0.001) and desire for cigarettes within 10 min of use (F(3, 727) = 26.1, p < 0.001). The NC induced fewer adverse side effects than other NRT and was judged to be more enjoyable (F(3, 87) = 13.56, p < 0.001) and satisfying to use (F(3, 92) = 12.35, p < 0.001).


The ‘Nicotine Cannon’ is at least as effective as equivalent NRT in reducing withdrawal symptoms and more acceptable to users, suggesting that it would be a useful addition to existing NRT. The acceptability profile could make it particularly useful as a ‘harm reduction’ tool.


Nicotine replacement therapy Withdrawal symptoms Acceptability Smoking cessation Novel treatment 


  1. Anthony J, Warner L, Kessler R (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharm 2:244–268CrossRefGoogle Scholar
  2. Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R (2011) Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction 106(1):197–204Google Scholar
  3. Bolliger CT, van Biljon X, Axelsson A (2007) A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration 74:196–201PubMedCrossRefGoogle Scholar
  4. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M (2010) Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control 19:98–103PubMedCrossRefGoogle Scholar
  5. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG (2007) Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 32:912–923PubMedCrossRefGoogle Scholar
  6. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191PubMedCrossRefGoogle Scholar
  7. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A (1999) Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159:2033–2038PubMedCrossRefGoogle Scholar
  8. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J (1989) Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict 84:791–799PubMedCrossRefGoogle Scholar
  9. Jarvis MJ, Belcher M, Vesey C, Hutchison DC (1986) Low cost carbon monoxide monitors in smoking assessment. Thorax 41:886–887PubMedCrossRefGoogle Scholar
  10. Krueger C, Tian L (2004) A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points. Biol Res Nurs 6:151–157PubMedCrossRefGoogle Scholar
  11. McEwen A, West R, Gaiger M (2008) Nicotine absorption from seven current nicotine replacement products and a new wide-bore nicotine delivery device. J Smoking Cessation 3:117–123Google Scholar
  12. McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, Whittaker R, Hajek P (2010) A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction 105:1290–1298PubMedCrossRefGoogle Scholar
  13. MHRA (2010) MHRA Public Assessment Report: the use of nicotine replacement therapy to reduce harm in smokers. Medicine and Healthcare Products Regulatory Agency, LondonGoogle Scholar
  14. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P (2009) Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 338:b1024PubMedCrossRefGoogle Scholar
  15. Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M (2010) Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol 18:385–394PubMedCrossRefGoogle Scholar
  16. Royal College of Physicians (2000) Nicotine addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians of London, LondonGoogle Scholar
  17. Royal College of Physicians (2007) Harm reduction in nicotine addiction: helping people who can't quit. Royal College of Physicians of London, LondonGoogle Scholar
  18. Shahab L, West R (2010) Public support in England for a total ban on the sale of tobacco products. Tob Control 19:143–147PubMedCrossRefGoogle Scholar
  19. Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, Pinney JM, Chau T (2009) Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav 91:380–384PubMedCrossRefGoogle Scholar
  20. Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG (2006) Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl) 184:637–644CrossRefGoogle Scholar
  21. Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64:366–379PubMedCrossRefGoogle Scholar
  22. Shiffman SM, Jarvik ME (1976) Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl) 50:35–39CrossRefGoogle Scholar
  23. Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146Google Scholar
  24. Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, Feyerabend C (1992) Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324–329PubMedCrossRefGoogle Scholar
  25. Thornley S, McRobbie H, Lin RB, Bullen C, Hajek P, Laugesen M, Senior H, Whittaker R (2009) A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob Res 11:715–721PubMedCrossRefGoogle Scholar
  26. Watkins SS, Koob GF, Markou A (2000) Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2:19–37PubMedCrossRefGoogle Scholar
  27. West R (2009) The multiple facets of cigarette addiction and what they mean for encouraging and helping smokers to stop. COPD 6:277–283PubMedCrossRefGoogle Scholar
  28. West R, Hajek P (2004) Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl) 177:195–199CrossRefGoogle Scholar
  29. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A (2000) A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 149:198–202CrossRefGoogle Scholar
  30. West R, Shiffman S (2007) Fast facts: smoking cessation. Health, OxfordGoogle Scholar
  31. West R, Ussher M, Evans M, Rashid M (2006) Assessing DSM-IV nicotine withdrawal symptoms: a comparison and evaluation of five different scales. Psychopharmacology (Berl) 184:619–627CrossRefGoogle Scholar
  32. WHO (1998) Action for tobacco control. In: Guideline for controlling and monitoring the tobacco epidemic. World Health Organization, GenevaGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Cancer Research UK Health Behaviour Research Centre, Department of Epidemiology and Public HealthUniversity College LondonLondonUK

Personalised recommendations